Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 7/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872523 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BPNPLMNA | |
| SCHEMBL5983051 | 0.86 | DNMT1 (0.58) | DNMT1ADRB1DNMT3BADK | |
| SCHEMBL5983046 | 0.86 | DNMT1 (0.58) | DNMT1ADRB1DNMT3BADK | |
| SCHEMBL17383945 | 0.81 | DNMT1 (0.46) | DNMT1ADRB1DNMT3BPNPLMNA | |
| SCHEMBL26694397 | 0.81 | DNMT1 (0.54) | DNMT1ADRB1DNMT3B | |
| SCHEMBL26872086 | 0.81 | DNMT1 (0.54) | DNMT1ADRB1DNMT3B | |
| SCHEMBL14031656 | 0.81 | DNMT1 (0.54) | DNMT1ADRB1DNMT3B | |
| SCHEMBL5872494 | 0.81 | TK1 (0.60) | LMNASMN1; SMN2TK2TK1 | |
| SCHEMBL5872491 | 0.81 | TK1 (0.60) | LMNASMN1; SMN2TK2TK1 | |
| SCHEMBL30698161 | 0.80 | DNMT1 (0.53) | DNMT1ADRB1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057027-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-6962783-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-6875593-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | FROEHLER BRIAN (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1256589-A2 | Oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DNMT1 336/4885ADRB1 3612/4885DNMT3B 305/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | DNMT1 336/4885ADRB1 3612/4885DNMT3B 305/4885 |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DNMT1 336/4885ADRB1 3612/4885DNMT3B 305/4885 |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DNMT1 336/4885ADRB1 3612/4885DNMT3B 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.